Literature DB >> 11121408

Differential effects of leukocyte common antigen-related protein on biochemical and biological activities of RET-MEN2A and RET-MEN2B mutant proteins.

S Qiao1, T Iwashita, T Furukawa, M Yamamoto, G Sobue, M Takahashi.   

Abstract

Protein-tyrosine-phosphatases (PTPs), in conjunction with protein-tyrosine kinases, play essential regulatory roles in diverse cellular activities by modulating the phosphorylation state of target proteins. Leukocyte common antigen-related (LAR) protein is a widely expressed receptor-type protein-tyrosine-phosphatase that is implicated in the regulation of intracellular signaling triggered by both cell adhesion and peptide growth factors. The gene for LAR is localized to human chromosome 1p32, a region frequently deleted in tumors of neuroectodermal origin, including neuroblastoma, pheochromocytoma, and medullary thyroid carcinoma. On the other hand, the RET gene codes for a transmembrane tyrosine kinase and is responsible for the development of multiple endocrine neoplasia (MEN) 2A and 2B. To explore the potential role of LAR in RET tyrosine kinase activity and RET-induced signal transduction, we cotransfected LAR and RET with a MEN2A or MEN2B mutation (designated RET-MEN2A or RET-MEN2B) into the NIH 3T3 cell line. Here we show that LAR reduces the constitutive tyrosine autophosphorylation and kinase activity of RET-MEN2A but not RET-MEN2B, accompanying a significant decrease of phosphorylation of phospholipase Cgamma, AKT, and ERK1/2. Interestingly, LAR expression significantly decreased the levels of disulfide-linked RET-MEN2A dimerization. Moreover, reduced oncogenic activity of RET-MEN2A by overexpression of LAR was observed both by an in vitro colony formation assay and by in vivo tumorigenicity in scid mice. These results thus suggest that LAR may contribute to deactivation of the RET-MEN2A mutant protein and reduction of its oncogenic activity in vivo.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11121408     DOI: 10.1074/jbc.M008744200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  7 in total

1.  Receptor type protein tyrosine phosphatases (RPTPs) - roles in signal transduction and human disease.

Authors:  Yiru Xu; Gary J Fisher
Journal:  J Cell Commun Signal       Date:  2012-08-01       Impact factor: 5.782

2.  Overexpression of leucocyte common antigen (LAR) P-subunit in thyroid carcinomas.

Authors:  N Konishi; K Tsujikawa; H Yamamoto; E Ishida; M Nakamura; K Shimada; K Yane; H Yamashita; S Noguchi
Journal:  Br J Cancer       Date:  2003-04-22       Impact factor: 7.640

3.  Maturation of ureter-bladder connection in mice is controlled by LAR family receptor protein tyrosine phosphatases.

Authors:  Noriko Uetani; Kristen Bertozzi; Melanie J Chagnon; Wiljan Hendriks; Michel L Tremblay; Maxime Bouchard
Journal:  J Clin Invest       Date:  2009-03-09       Impact factor: 14.808

4.  The oncogenic activity of RET point mutants for follicular thyroid cells may account for the occurrence of papillary thyroid carcinoma in patients affected by familial medullary thyroid carcinoma.

Authors:  Rosa Marina Melillo; Anna Maria Cirafici; Valentina De Falco; Marie Bellantoni; Gennaro Chiappetta; Alfredo Fusco; Francesca Carlomagno; Antonella Picascia; Donatella Tramontano; Giovanni Tallini; Massimo Santoro
Journal:  Am J Pathol       Date:  2004-08       Impact factor: 4.307

Review 5.  Gene therapeutic approaches for medullary thyroid carcinoma treatment.

Authors:  Matthias Drosten; Brigitte M Pützer
Journal:  J Mol Med (Berl)       Date:  2003-06-14       Impact factor: 4.599

6.  Neuroendocrine-derived peptides promote prostate cancer cell survival through activation of IGF-1R signaling.

Authors:  John O DaSilva; George P Amorino; Eli V Casarez; Bradley Pemberton; Sarah J Parsons
Journal:  Prostate       Date:  2012-11-28       Impact factor: 4.104

7.  PTPRA Phosphatase Regulates GDNF-Dependent RET Signaling and Inhibits the RET Mutant MEN2A Oncogenic Potential.

Authors:  Leena Yadav; Elina Pietilä; Tiina Öhman; Xiaonan Liu; Arun K Mahato; Yulia Sidorova; Kaisa Lehti; Mart Saarma; Markku Varjosalo
Journal:  iScience       Date:  2020-01-31
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.